Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Triple Therapy with Methotrexate Effective, Cheaper in RA

Larry Hand  |  April 27, 2016

NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…

Abaloparatide May Boost BMD in Older Women with Osteoporosis

Lorraine L. Janeczko  |  April 26, 2016

NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…

CMS Commences 45-Day Open Payments Review & Dispute Period

From the College  |  April 18, 2016

On April 1, the Centers for Medicare and Medicaid Services (CMS) announced the beginning of the 45-day Open Payments Review and dispute period, which will conclude on May 15. After the review period concludes, on June 30, CMS will publish 2015 payment data along with updates to the 2013 and 2014 data. If you are…

Sifalimumab Shows Some Promise Against Lupus

Reuters Staff  |  April 15, 2016

NEW YORK (Reuters Health)—Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online on March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King’s College London and colleagues note that treatment of SLE presents a…

Hidradenitis Suppurativa Can Complicate Biologic Therapy

Will Boggs, MD  |  April 13, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa can complicate biologic therapy of chronic inflammatory diseases, according to a retrospective study from France and Belgium. Hidradenitis suppurativa (HS) often responds to treatment with biologic agents, but there have been scattered reports of patients developing HS while undergoing biologic therapy. Dr. Coline Faivre from Hôpital Edouard Herriot in Lyon,…

U.S., Canada Issue Joint Alert on Ransomware after Hospital Attacks

Jim Finkle  |  April 7, 2016

(Reuters)—The U.S. and Canada on Thursday issued a rare joint cyber alert, warning against a recent surge in extortion attacks that infect computers with viruses known as “ransomware,” which encrypt data and demand payments for it to be unlocked. The warning follows reports from several private security firms that they expect the crisis to worsen,…

U.S. to Raise Payments to Insurers for Medicare Advantage 2017 Plans

Caroline Humer  |  April 7, 2016

NEW YORK (Reuters)—U.S. health insurers that provide Medicare Advantage plans to elderly and disabled Americans will receive government payments in 2017 that are 0.85 percent higher on average than in 2016, reflecting small anticipated growth in medical costs, the U.S. Department of Health and Human Services said on Monday. Health and Human Services’ final plan…

Remicade Antibodies Cross-React to Biosimilars

Lorraine L. Janeczko  |  April 6, 2016

NEW YORK (Reuters Health)—Patients with antibodies to infliximab in Remicade should not be switched to biosimilars, researchers warn. “(The) antibodies will cross-react with the new biosimilar drug, potentially reducing clinical response,” Dr. Daniel Nagore, director of research and development at Progenika Biopharma in Derio, Spain, told Reuters Health by email. “The study highlights the importance…

FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Reuters Staff  |  April 6, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson’s drug Remicade (infliximab), to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, also known as infliximab-dyyb, is expected by some analysts to sell for a 25% discount to Remicade, which generated annual…

Self-Reported Knee Instability After Surgery Linked to Pain & Limited Mobility

Arthritis Care & Research  |  April 5, 2016

Patients with osteoarthritis often consider total knee replacement surgery to resolve pain and increase mobility. However, a recent study found that self-reported knee instability and pain are prevalent in patients both before and after primary unilateral total knee replacement surgery. One-third of the study’s participants still had knee instability after surgery, experiencing knee buckling and shifting associated with pain and limited activity. Using physical performance measurements, researchers linked self-reported knee instability following surgery to pain and poor lower-extremity muscle strength…

  • « Previous Page
  • 1
  • …
  • 65
  • 66
  • 67
  • 68
  • 69
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences